Mike Tuffin is set to become AHIP's President and CEO from January 8, 2024, succeeding Julie Simon Miller.
Beginning January 8, 2024, Mike Tuffin, MBA, will take on the role of president and CEO of AHIP.
Tuffin is succeeding Matthew Eyles, who led the health insurance industry's trade group for five years before stepping down in September 2023. Julie Simon Miller, AHIP’s general counsel, served as the interim CEO.
Tuffin has been the senior vice president for external affairs for UnitedHealth Group since 2015. He is coming back to AHIP having served as executive vice president for public affairs of the organization from 2003 to 2012.
Tuffin's leadership will improve the organization’s mission of representing over 100 diverse companies providing healthcare coverage for millions of consumers and families, according to an AHIP news release about selection of Tuffin.
The chair of AHIP’s Board of Directors, David Holmberg, mentioned in the press release that the search for the position was thorough when trying to find a “forward-looking leader and advocate with extensive healthcare experience.”
“As a corporate executive, association leader and consultant, Mike has demonstrated an ability to successfully lead teams, partner with key stakeholders and advance policy outcomes that are critical to the health and security of the people our industry serves,” Holmberg said.
“Millions of American families and employers count on AHIP’s members for their coverage and care and for support in navigating our complex health care system,” Tuffin said in the press release. “I am honored to join Julie and the high-performing AHIP team in advancing this critical work.”
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More